Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies

A research study of liver perfusion (how blood flows to the liver over time). We hope to learn whether perfusion characteristics of liver masses may be predictive of response to treatment and whether liver perfusion characteristics can be used to follow response to treatment.

Stanford is now accepting new patients for this trial. Please contact Elizabeth Chitouras at 650-498-0623 for more information.



  • procedure : CT perfusion

Phase: N/A


Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

3.1.1 Patients with suspected or biopsy-proven liver masses including unresectable hepatocellular carcinoma (HCC), unresectable colon cancer metastases to the liver, and metastatic neuroendocrine tumors to the liver will be eligible for enrollment. 3.1.2 Patients who have undergone prior chemotherapy more than one year prior to the study are eligible for enrollment. 3.1.4 Patients must be 18 years or older. Patients must not be pregnant and, if of child-bearing age, must take precautions not to become pregnant. 3.1.5 No life expectancy restrictions. 3.1.6 ECOG and Karnofsky Performance Status will not be employed. 3.1.7 Patients with renal failure are ineligible for this study (Glomerular filtration rate (GFR) must be > 60) 3.1.8 Ability to understand and willingness to sign a written informed consent document.

External Links

Explore related trials

Contact information

Primary Contact:

Elizabeth Chitouras 650-498-0623

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: